Wilmington Savings Fund Society FSB Purchases Shares of 1,329 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the third quarter, Holdings Channel.com reports. The firm acquired 1,329 shares of the biopharmaceutical company’s stock, valued at approximately $97,000.

Other institutional investors have also recently modified their holdings of the company. Calamos Advisors LLC boosted its stake in Intra-Cellular Therapies by 86.1% in the second quarter. Calamos Advisors LLC now owns 16,404 shares of the biopharmaceutical company’s stock worth $1,124,000 after buying an additional 7,590 shares in the last quarter. EFG Asset Management North America Corp. boosted its stake in shares of Intra-Cellular Therapies by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 34,452 shares of the biopharmaceutical company’s stock valued at $2,357,000 after purchasing an additional 163 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Intra-Cellular Therapies by 325.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 69,696 shares of the biopharmaceutical company’s stock valued at $4,773,000 after purchasing an additional 53,322 shares during the last quarter. Summit Securities Group LLC purchased a new position in Intra-Cellular Therapies in the 2nd quarter worth $56,000. Finally, Legato Capital Management LLC raised its position in Intra-Cellular Therapies by 67.7% in the 2nd quarter. Legato Capital Management LLC now owns 24,582 shares of the biopharmaceutical company’s stock worth $1,684,000 after purchasing an additional 9,923 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Trading Down 0.8 %

ITCI opened at $83.45 on Friday. The company has a market cap of $8.85 billion, a price-to-earnings ratio of -95.92 and a beta of 0.95. The stock has a fifty day simple moving average of $83.64 and a two-hundred day simple moving average of $77.34. Intra-Cellular Therapies, Inc. has a 12-month low of $62.78 and a 12-month high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million for the quarter, compared to analysts’ expectations of $172.30 million. During the same period last year, the business earned ($0.25) earnings per share. The company’s revenue was up 39.0% on a year-over-year basis. On average, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Activity

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Michael Halstead sold 22,869 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Company insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ITCI shares. Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $68.00 to $92.00 in a research note on Friday, September 6th. JPMorgan Chase & Co. raised their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada increased their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.